SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Viral Safety of Human Plasma–Derived Medicinal Products: Impact of Regulation Requirements
2 references·1 citing·12 second hop
Viral Safety of Human Plasma–Derived Medicinal Products: Impact of Regulation Requirements (2013)Viral Safety of Human Plasma–Derived Medi…Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations (2011)Donor Testing and Risk: Curre…Tolerability of risk from nuclear power stations (1988)Tolerability of risk from nuc…Challenges associated with access to plasma‐derived medicinal products in low middle‐income and low‐income countries (2023)Challenges associated with ac…The Risk of Transfusion-Transmitted Viral Infections (1996)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)Risk factors for human immunodeficiency virus infection among Brazilian blood donors: a multicentre case–control study using audio computer‐assisted structured interviews (2013)The Use of Rapid Diagnostic Tests for Transfusion Infectious Screening in Africa: A Literature Review (2014)Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016 (2020)An Anatomy of Risk (1977)Risk Perception Research (2000)Allocating Risks and Suffering: Some Hidden Traps (2011)Philosophy of Law (2011)“Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed! (2014)Stepwise access to safe plasma proteins in resource‐constrained countries: Local production and pathways to fractionation—Report of an International Society of Blood Transfusion Workshop (2022)
this work references cited by second hop

References

  • 1988Tolerability of risk from nuclear power stations252 cited
  • 2011Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations198 cited

Cited by

  • 2023Challenges associated with access to plasma‐derived medicinal products in low middle‐income and low‐income countries8 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work